Skip to main content
PAINCHEK LTD logo

PAINCHEK LTD — Investor Relations & Filings

Ticker · PCK ISIN · AU000000PCK6 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 798 across all filing types
Latest filing 2026-05-25 Director's Dealing
Country AU Australia
Listing ASX PCK

About PAINCHEK LTD

https://www.painchek.com

PainChek Ltd develops digital pain assessment solutions utilizing artificial intelligence and facial recognition technology. The company's primary application is designed to detect and quantify pain in individuals who cannot communicate verbally, such as those living with dementia or other cognitive impairments. By analyzing micro-facial expressions via a mobile device camera, the software generates an objective pain score to assist healthcare professionals in clinical decision-making and medication management. The platform is primarily deployed in residential aged care, hospital, and home care environments. Additionally, the company provides a specialized version for infant pain assessment. The technology is clinically validated and maintains regulatory clearances for use in various global healthcare markets, aiming to replace subjective manual assessment tools with automated, data-driven insights.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice 2 pages 223.9KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3X “Initial Director’s Interest Notice” disclosing the director’s securities interests under Listing Rule 3.19A.1. This type of filing reports insider transactions and director shareholdings. It matches the Director’s Dealing category.
2026-05-25 English
Lil Bianchi appointed Non-Executive Chair of PainChek 3 pages 256.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement detailing the appointment of a new Non-Executive Chair and the transition of the outgoing Chair to Non-Executive Director. It solely announces changes to the company’s board composition, with no financial data or presentation materials. This matches the definition of Board/Management Information (Code: MANG).
2026-05-24 English
PainChek secures A$5.5m note to fund US expansion 4 pages 275.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the terms and conditions of a A$5.5 million unsecured convertible note financing (fundraising) for U.S. expansion and working capital, including interest, maturity, conversion mechanics, and listing rule compliance. It is a capital/financing update rather than a report or other change notice.
2026-05-21 English
Proposed issue of securities - PCK 7 pages 25.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX Appendix 3B form detailing the proposed issue of convertible notes and attaching options by PainChek Ltd, including number of securities, issue dates, pricing, conditions, and listing rule details. This is clearly an announcement of a new securities issue/capital change, matching the "Share Issue/Capital Change" category (Code: SHA). It is not a full financial report or earnings release, but a capital issuance announcement under listing rules.
2026-05-21 English
Quarterly Activities/Appendix 4C Cash Flow Report 14 pages 580.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 April 2026, titled '31 March 2026 Quarterly Update and Appendix 4C'. It provides detailed quarterly operational and financial updates including licence sales, ARR, cash reserves, market commentary, partnerships, product updates, research activities, and unaudited revenue figures for the 9 months to March 2026. The presence of Appendix 4C (a standard quarterly cash flow report for ASX-listed companies) and the focus on quarterly performance and cashflow indicate this is a quarterly report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, nor is it a full annual report or earnings release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English
Landmark Sabra North America deployment targeting 20k beds 3 pages 218.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 14 April 2026 from PainChek Ltd regarding a new commercial agreement with Sabra Health Care REIT. It details the terms of a Master Services Agreement for deployment of PainChek's solution across Sabra's facilities. The content focuses on the business deal, pricing, strategic implications, and company background. There are no financial statements, regulatory filings, or detailed financial performance data included. The document is a corporate announcement about a commercial partnership and funding model, not a financial report, earnings release, or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a general corporate announcement about a business agreement, best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2026-04-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.